Organization
Azienda Ospedaliero Universitaria Careggi, University of Florence
3 abstracts
Abstract
IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESA).Org: Yale School of Medicine and Yale Cancer Center, Yale University, Leipzig University Hospital, Azienda Ospedaliero Universitaria Careggi, University of Florence, Hôpital Saint-Louis, Université de Paris, Sylvester Comprehensive Cancer Center, University of Miami Health System,
Abstract
Efficacy of imetelstat on red blood cell (RBC)-transfusion independence (TI) in the absence of platelet transfusions or myeloid growth factors in IMerge.Org: Yale University, Azienda Ospedaliero Universitaria Careggi, University of Florence, University of Florence, AOUC, Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, University Hospital Leipzig,
Abstract
Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT).Org: Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands, University Medical Center Utrecht, Sotiria General Hospital, Azienda Ospedaliero Universitaria Careggi, University of Florence, Centre Hospitalier Universitaire de Liège,